GlobalData.

Biocon launches first US manufacturing facility in Cranbury, NJ

Biocon Generics will operate the new FDA-approved manufacturing facility. Credits: Biocon. · Investment Monitor

Sarthak Agarwal
September 15, 2025 • 2 min read

Biocon Generics (BGI), a wholly owned subsidiary of Indian biopharmaceutical company Biocon Ltd, has unveiled its new manufacturing facility in Cranbury, New Jersey, US.

Biocon acquired the site from Eywa Pharma for $7.7m in September 2023. Since the purchase, it has invested over $30m to establish an advanced plant capable of producing up to two billion tablets annually. The company has already commercialised a few products from the facility, with additional launches planned for the future.



The new facility aims to diversify Biocon's manufacturing capabilities, enhance its supply chain, and expand its global presence. The facility also advances the company's US operations by providing quicker access to essential therapies. Additionally, it strengthens relationships with partners and healthcare providers, ultimately benefiting patients nationwide.

Kiran Mazumdar-Shaw, chairperson of Biocon, remarked that the new facility marked a new chapter in Biocon's journey of global expansion.

Siddharth Mittal, CEO and managing director of Biocon, stated that the strategic investment brought them closer to patients, healthcare providers, and partners.

"The proximity allows us to deliver our vertically integrated medicines more efficiently to patients across the US and other markets. It also ensures supply chain resilience, enabling us to advance our mission of expanding access to affordable therapies worldwide," he added.

Phil Murphy, Governor of New Jersey, expressed his gratitude towards Biocon for its decision to open its first US manufacturing facility in New Jersey.

"For years, Biocon has provided high-quality medicines and treatments to millions of patients across the globe. This state-of-the-art facility marks a significant moment in Biocons's global expansion and reinforces New Jersey's reputation as the medicine chest to the world," Murphy added.

The Cranbury facility adds to the company's growing presence in the US. Last year, in September 2024, it opened its North American headquarters in Bridgewater, New Jersey.

"Biocon launches first US manufacturing facility in Cranbury, NJ" was originally created and published by Investment Monitor, a GlobalData owned brand.

View Comments

Terms and Privacy Policy Your Privacy Choices